| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2023―Dez―12 |
Progress of SARS-CoV-2 Main protease peptide-like inhibitors |
Xiaoyong Liu, Xiaoli Ren, Miao Hua, Fang Liu, Xiaoping Ren, Chaoya Sui, et al. (+6) Qing Li, Fen Luo, Zhiyong Jiang, Ziqiao Xia, Jingxia Chen, Bing Yang |
| 2 |
[GO] |
2023―Nov―13 |
Discovery and development of COVID-19 vaccine from laboratory to clinic |
Venkatesan Saravanan, Bharath Kumar Chagaleti, Pavithra Lakshmi Narayanan, Vijay Babu Anandan, Haritha Manoharan, G.V. Anjana, et al. (+6) Ramalingam Peraman, S. Karthik Raja Namasivayam, M. Kavisri, Jesu Arockiaraj, Kathiravan Muthu Kumaradoss, Meivelu Moovendhan |
| 3 |
[GO] |
2023―Aug―11 |
Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors |
Hong-Lei Bao, Gao Tu, Qiu Yue, Pei Liu, Hui-Li Zheng, Xiao-Jun Yao |
| 4 |
[GO] |
2022―Dez―01 |
Combining Computational and Experimental Evidence on the Activity of Antimalarial Drugs on
Papain-Like
Protease of
SARS-CoV
-2: A Repurposing Study |
Giovanni Ribaudo, Xiaoyun Yun, Alberto Ongaro, Erika Oselladore, Jerome P. L. Ng, Richard K. Haynes, et al. (+5) Betty Yuen Kwan Law, Maurizio Memo, Vincent Kam Wai Wong, Paolo Coghi, Alessandra Gianoncelli |
| 5 |
[GO] |
2022―Nov―11 |
Design, Synthesis, and Biological Evaluation of Novel Ruxolitinib and Baricitinib Analogues for Potential Use Against COVID-19 |
Qin Lin, Jun Li, Yinping Wang, Jie Zang |
| 6 |
[GO] |
2022―Jul―06 |
Hydrogen Bonding Penalty Used for
Virtual Screening to Discover Potent Inhibitors for
Papain-Like
Cysteine Proteases of
SARS-CoV
-2 |
Guangjian Zhao, Xiaochun Liu, Suyun Wang, Zhongyue Bai, Siyu Zhang, Yifan Wang, et al. (+2) Haibo Yu, Ximing Xu |
| 7 |
[GO] |
2022―Feb―20 |
SARS-CoV-2 and its variants of concern including Omicron: looks like a never ending pandemic |
Ranjan K. Mohapatra, Satwik Kuppili, Tarun Kumar Suvvari, Venkataramana Kandi, Ajit Behera, Sarika Verma, et al. (+5) Susanta K. Biswal, Taghreed H. Al-Noor, Marei M. El-ajaily, Ashish K. Sarangi, Kuldeep Dhama |
| 8 |
[GO] |
2021―Dez―16 |
Active site-based analysis of structural proteins for drug targets in different human
Coronaviruses |
Khadijeh Ahmadi, Farnaz Zahedifard, Ladan Mafakher, Mohammad Ali Einakian, Tayebeh Ghaedi, So�h Kavousipour, et al. (+5) Sobhan Faezi, Afsaneh karmostaji, Khojasteh Sharifi-Sarasiabi, Hamed Gouklani, Mehdi Hassaniazad |
| 9 |
[GO] |
2021―Okt―29 |
Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study |
Haidar Saify Nabiabad, Massoume Amini, Serwet Demirdas |
| 10 |
[GO] |
2021―Sep―22 |
Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray |
Annekathrin Haberland, Johannes Müller |
| 11 |
[GO] |
2021―Mai―28 |
SARS-CoV-2 first contact: spike-ACE2 interactions in COVID-19 |
Salvatore Nesci |
| 12 |
[GO] |
2021―Apr―24 |
Computational Design and Modeling of Nanobodies toward SARS-CoV-2 Receptor Binding Domain |
Jingyi Yang, Zhao Zhang, Fengyuan Yang, Haiwei Zhang, Haibo Wu, Feng Zhu, Weiwei Xue |
| 13 |
[GO] |
2021―Jan―02 |
Novel QSAR model to predict Activity of natural Products against Covid-19 |
Yaru Si, Xinyue Xu, Yingfeng Hu, Hongzong Si, Honglin Zhai |
| 14 |
[GO] |
2020―Dez―08 |
Repurposing potential of FDA approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm |
Akalesh K. Verma, Rohit Aggarwal |
| 15 |
[GO] |
2020―Jul―12 |
The recent challenges of highly contagious COVID-19; causing respiratory infections: symptoms, diagnosis, transmission, possible vaccines, animal models and immunotherapy |
Ranjan K. Mohapatra, Lucia Pintilie, Venkataramana Kandi, Ashish K. Sarangi, Debadutta Das, Raghaba Sahu, Lina Perekhoda |
|
